NIAID Research on Chlamydia
Scientists are looking for better ways to diagnose, treat, and prevent chlamydia. For example, National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Rocky Mountain Laboratories are developing a vaccine to prevent C. trachomatis infection. The vaccine being tested is a single-component vaccine that is designed to protect against all 15 chlamydia varieties. Studies have already shown that the vaccine can prevent laboratory cells from becoming infected.
Another prevention strategy being pursued is the development of topical microbicides (preparations that can be inserted into the vagina to prevent infection) that are effective and easy for women to use.
To better understand the pathogenesis of C. trachomatis, researchers are also examining the organism’s genetic makeup. NIAID-supported scientists determined the complete genome (genetic blueprint) for C. trachomatis. The genome represents an encyclopedia of information about the bacteria. This accomplishment is giving scientists important information as they identify new targets for therapeutics, diagnostics and vaccines.